| 1701 |
LUCICAPIVA |
CAPAVASERTIB 160 MG |
TABLET |
BOTTLE |
IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF ADULT PATIENTS WITH HORMONE RECEPTOR POSITIVE, HYMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER WITH ONE OR MORE PIK3CA/AKT1/PTEN ALTERATION FOLLOWING PROGRESSION ON AT LEAST ONE ENDOCRINE BASED REGIMENT ON THE METASTATIC SETTING OR RECURRENT ON OR WITHIN 12 MONTHS OF CONPLETING ADJUVANT THERAPY |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
08 L 1167/24 |
21-AUG-2024 |
20-AUG-2027 |
View |
| 1702 |
LUCICAPIVA |
CAPAVASERTIB 200 MG |
TABLET |
BOTTLE |
IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF ADULT PATIENTS WITH HORMONE RECEPTOR POSITIVE, HYMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER WITH ONE OR MORE PIK3CA/AKT1/PTEN ALTERATION FOLLOWING PROGRESSION ON AT LEAST ONE ENDOCRINE BASED REGIMENT ON THE METASTATIC SETTING OR RECURRENT ON OR WITHIN 12 MONTHS OF CONPLETING ADJUVANT THERAPY |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
08 L 1160/24 |
21-AUG-2024 |
20-AUG-2027 |
View |
| 1703 |
LUCICAPMA |
CAPMATINIB 200 MG |
TABLET |
BOTTLE |
TREATMENT OF NON SMALL CELL LUNG CANCER |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
07 L 0996/23 |
31-JUL-2023 |
30-JUL-2026 |
View |
| 1704 |
LUCICER |
CERITINIB 150 MG |
CAPSULE |
BOTTLE |
TREATMENT OF PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER WHOSE TUMORS ARE ANAPLASTIC LYMPHOMA KINASE POSITIVE |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
06 L 1126/24 |
21-JUN-2024 |
20 JUN 2027 |
View |
| 1705 |
LUCICRIZ |
CRIZOTINIB 250 MG |
CAPSULE |
BOTTLE |
TO TREAT NON SMALL CELL LUNG CANCER THAT SPREAD TO NEARBY TISSUE OR OTHER PARTS OF THE BODY |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
04 L 0964/23 |
28-APR-2023 |
27-APR-2026 |
View |
| 1706 |
LUCICYP |
CYPROTERONE ACETATE 50 MG |
TABLET |
BLISTERPACK |
INDICATION IN FEMALE: SEVERE SIGN OF ANDROGENISATION E.G.VERY SEVERE HIRSUTISM, ANDROGEN DEPENDENT SEVERE LOSS OF SCLAP HAIR EVENTUALLY RESULTING IN BALDNESS, OFTEN ATTENED BY SEVERE FORMS OF ACNE OR SEBORROEA. INDICATION IN MALE: REUCTION OF DRIVES IN SEXUAL DEVIATION |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
11 L 1038/23 |
17-NOV-2023 |
16-NOV-2026 |
View |
| 1707 |
LUCIDABRA |
DABRAFENIB 75 MG |
CAPSULE |
BOTTLE |
AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATION. |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
10 L 1025/23 |
10-OCT-2023 |
09-OCT-2026 |
View |
| 1708 |
LUCIDAC |
DACOMITINIB 15 MG |
FILM COATED TABLET |
BOTTLE |
TREATMENT OF PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATION |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
06 L 1115/24 |
21-JUN-2024 |
20 JUN 2027 |
View |
| 1709 |
LUCIDAC |
DACOMITINIB 45 MG |
FILM COATED TABLET |
BOTTLE |
TREATMENT OF PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION MUTATION |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
06 L 1116/24 |
21-JUN-2024 |
20 JUN 2027 |
View |
| 1710 |
LUCIDAP |
DAPRODUSTAT 1 MG |
FILM COATED TABLET |
BOTTLE |
FOR THE TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST FOUR MONTHS |
NULL |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LUCIUS PHARMACEUTICALS(LAO) CO.,LTD |
LAOS |
CERTIFICATE RELEASED |
06 L 1114/24 |
21-JUN-2024 |
20 JUN 2027 |
View |
